HALO logo
halo search icon
ORY
Oryzon Genomics SA

ORY · Oryzon Genomics SA

2.63

EUR
-0.07 (-2.593%)
08/10/2026 12:00:00 AM
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

Euro227.70M

PE

27.80

EV/EBITDA

112.5

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 08/10/2026 12:00:00 AM

Price Chart

Description

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.

  • All-Companies
  • All-Consensus
  • HALO 100
  • HALO 200
  • HALO 50
  • HALO All
  • HALO Balance Sheet
  • HALO Consensus Value
  • Hammer Bearish (Realtime)
  • Near Support
  • Near Support (Realtime)

Key Fundamentals

EPS 3 yr Growth

-56.20%

EBITDA Margin

N/A

Operating Cashflow

-€2m

Free Cash Flow Return

-2.40%

ROIC

-2.60%

Interest Coverage

-10.30

Quick Ratio

1.90

Performance

52 weeks range

Low 2.6 - 4.02

Trade Value (12mth)

US$442,287.00

1 week

-2.81%

1 month

-2.67%

YTD

-16.15%

1 year

-26.43%

All time high

5.25

Additional Data

Shares Outstanding (Fully Diluted)

78m

HALO Sector

Healthcare

Next Company Report Date

04-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

EUR

Short Sell (% of issue)

0.00

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Neutral

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

No announcements available.

Key Stakeholders

NameTitle
Carlos Manuel Buesa ArjolIndividual
José-Maria Ventura FerreroIndividual
Tamara MaesIndividual
Oryzon Genomics SAPublic Company

See beyond the curve.

One solution for research, investing and model portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Oryzon Genomics SA (ORY:MCE)?
Halo FAQ
The current share price of Oryzon Genomics SA (ORY:MCE) is EUR€2.63.
2
What is the 52-week high share price for Oryzon Genomics SA (ORY:MCE)?
Halo FAQ
The 52-week high share price for Oryzon Genomics SA (ORY:MCE) is EUR€4.02.
3
What is the 52-week low share price for Oryzon Genomics SA (ORY:MCE)?
Halo FAQ
The 52-week low share price for Oryzon Genomics SA (ORY:MCE) is EUR€2.60.
4
What is the dividend yield for Oryzon Genomics SA (ORY:MCE)?
Halo FAQ
Oryzon Genomics SA (ORY:MCE) does not pay a dividend.
5
What was Oryzon Genomics SA (ORY:MCE) last dividend payment?
Halo FAQ
Oryzon Genomics SA (ORY:MCE) does not pay a dividend.
6
What is the franking level for Oryzon Genomics SA (ORY:MCE)?
Halo FAQ
Oryzon Genomics SA (ORY:MCE) has a franking level of 0.00%.
7
In which sector is Oryzon Genomics SA (ORY:MCE) classified?
Halo FAQ
Oryzon Genomics SA (ORY:MCE) is classified in the Healthcare.
8
What is the price-to-earnings (P/E) ratio for Oryzon Genomics SA (ORY:MCE)?
Halo FAQ
The current P/E ratio for Oryzon Genomics SA (ORY:MCE) is 27.80.